What question did this study set out to answer?

To evaluate the prevalence of abnormal objective biomarkers reflecting systemic inflammation, oxidative stress, neurotransmitter turnover, and micronutrient status in patients with chronic pain.

January 14, 2020Pain PhysicianOpen Access

An Analysis of Biomarkers in Patients withChronic Pain

View Full Paper

Ask AI

Bookmark

To evaluate the prevalence of abnormal objective biomarkers reflecting systemic inflammation, oxidative stress, neurotransmitter turnover, and micronutrient status in patients with chronic pain.
Retrospective, observational study analyzing a novel pain-specific biomarker test panel across 17,834 unique patient clinical samples at a national reference laboratory between July and December 2018.
Biomarker concentrations were classified as abnormal when falling outside 95% confidence interval reference ranges established in a healthy cohort without chronic pain or opioid use.
Overall, 77% of patients with chronic pain exhibited at least one abnormal biomarker result (n = 13,765).
Frequent markers of inflammation and oxidative stress included elevated quinolinic acid in 29% (n = 5,107), acrolein metabolite 3-hydroxypropyl mercapturic acid in 21% (n = 3,667), and elevated pyroglutamate (indicating glutathione depletion) in 19% (n = 3,314).
Nutritional and neurochemical abnormalities included elevated xanthurenic acid (vitamin B6 insufficiency) in 17% (n = 3,025), elevated methylmalonic acid (vitamin B12 deficiency) in 10% (n = 1,827), and abnormally low neurotransmitter metabolites in 8% (n = 1,456).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective observational study reveals abnormal metabolic and inflammatory biomarkers in chronic pain, highlighting targets for nonopioid therapies.

Cite This Study

Joshua Gunn (2020) studied this question.

synapsesocial.com/papers/6a7639c1f1e99ff85ab248de https://doi.org/10.36076/ppj.2020/23/e41

View Full Paper

Ask AI

Bookmark

Implication

Retrospective observational study reveals abnormal metabolic and inflammatory biomarkers in chronic pain, highlighting targets for nonopioid therapies.

An Analysis of Biomarkers in Patients withChronic Pain

Key Points

Discussion

Implication

Cite This Study

An Analysis of Biomarkers in Patients withChronic Pain

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider